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ABSTRACT OF THESIS

REINFORCING, SUBJECTIVE, AND COGNITIVE EFFECTS OF
METHAMPHETAMINE DURING D-AMPHETAMINE MAINTENANCE
Translational research suggests that agonist replacement may be a viable
treatment approach for managing methamphetamine dependence. This study
sought to determine the effects of d-amphetamine maintenance on
methamphetamine self-administration in stimulant using participants. A cognitive
battery was used to determine the performance effects of methamphetamine
alone and during d-amphetamine maintenance. During each maintenance
condition, participants first sampled a dose of intranasal methamphetamine then
had the opportunity to respond on a progressive ratio task to earn portions of the
sampled dose. Subject-rated drug-effect and physiological measures were
completed prior to and after sampling methamphetamine. Methamphetamine was
self-administered as function of dose regardless of the maintenance condition.
Methamphetamine produced prototypical subject-rated effects, some of which
were attenuated by d-amphetamine maintenance. Methamphetamine was well
tolerated during d-amphetamine maintenance and no adverse events occurred.
The self-administration results are concordant with those of clinical trials that
show d-amphetamine did not reduce methamphetamine use. Generally, there
was no difference in cognitive performance after methamphetamine
administration during both placebo and d-amphetamine maintenance. Overall damphetamine does not appear to be a viable treatment for preventing
methamphetamine relapse, but translational literature suggests that other agonist
medications or the combination of pharmacotherapy and behavioral therapies
may be effective.
Keywords: methamphetamine, d-amphetamine, self-administration, subject-rated
drug-effects, cognitive performance
___Erika Pike___
____2/1/13_____
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Chapter One. Significance and Background
Methamphetamine use disorders are a significant problem in the United
States. In 2011, 439,000 individuals over 12 years of age reported using
methamphetamine. The number of new users of methamphetamine 12 years of
age and older increased between 2010 and 2011 (Substance Abuse and Mental
Health Services Administration (SAMHSA), 2011; SAMHSA, 2012). Not only are
the number of individuals using methamphetamine increasing, but the cost to
society, including premature death, health care costs, and costs of incarceration,
is staggering. Using the most recently available data, the estimated total cost of
methamphetamine abuse in the United States was over $23 billion in 2005
(Nicosia, Pacula, Kilmer, Lundberg, & Chiesa, 2009). The increasing number of
individuals using methamphetamine and the high cost to society contribute to the
importance of identifying an effective treatment for methamphetamine abuse, as
no universally effective treatments are currently available.
Below I review the available therapeutic approaches for methamphetamine
dependence that have been empirically tested.
Behavioral Therapy
Behavioral

therapies

that

have

been

tested

for

treatment

of

methamphetamine abuse include motivational interviewing, cognitive behavioral
therapy, relapse prevention, the Matrix Model, and contingency management.
Motivational interviewing is a type of therapy designed to help increase an
individual’s motivation to change their substance use patterns (Baker, Boggs, &
Lewin, 2001; Baker, et al., 2002; Baker, et al., 2005). Cognitive behavioral
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therapy is related to basic principles of conditioning and learning and involves
teaching individuals skills to stop or reduce their substance use (Lee & Rawson,
2008; Vocci & Montoya, 2009). Cognitive behavioral therapy has been expanded
into other more specific therapies, such as relapse prevention. Relapse
prevention aims to help individuals recognize and cope with situations and
feelings that may contribute to relapse in order to increase periods of abstinence
(Baker, Boggs, & Lewin, 2001; Baker, et al., 2005; Lee & Rawson, 2008). The
Matrix Model was designed specifically to address treatment needs of stimulant
abusers and is an intensive multi-week program that includes many types of
treatment such as relapse prevention, individual therapy, group sessions, and
family education. This model also encourages individuals to become involved in
social support groups, such as Alcoholics Anonymous (Obert, et al., 2000;
Rawson, et al., 1994, Rawson, et al., 2004; Vocci & Montoya, 2009).
Contingency management is a treatment model that provides incentives, such as
vouchers for goods or services or payment, for meeting set behavioral goals
(e.g., negative urine samples or self-reported abstinence) (for review see: Lee &
Rawson, 2008; Roll, 2007; and Vocci & Montoya, 2009; Roll, et al., 2006).
One example of a behavioral intervention that has been tested is contingency
management, which has shown promise as a potential treatment for
methamphetamine abuse. Methamphetamine abusing participants receiving
treatment, including contingency management, were more likely to provide
amphetamine or methamphetamine negative urine samples, have increased
retention in treatment, and have longer periods of abstinence (for review see:
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Lee & Rawson, 2008 and Roll, 2007; Vocci & Montoya, 2009; Rebak, Peck,
Dierst-Davies, Nuno, Kamien, & Amass, 2010; Roll, et al., 2006). While
contingency management seems promising, results at follow-up are inconsistent.
Some studies show maintained abstinence at follow-up, while others show that
the differences between contingency management and treatment as usual or no
treatment is not maintained at follow-up (for review see: Lee & Rawson, 2008
and Roll, 2007; Vocci & Montoya, 2009; Rebak, Peck, Dierst-Davies, Nuno,
Kamien, & Amass, 2010; Roll, et al., 2006). Recent reviews have shown similar
results with other cognitive and behavioral therapies (i.e., motivational
interviewing, cognitive behavioral therapy, and Matrix Model treatment), with
increased rates of stimulant negative urine samples, increased treatment
retention, and increased continuous abstinence compared to treatment as usual
or no treatment. However, beneficial effects of the treatments have not been
shown to be present at follow-up (Lee & Rawson, 2008; Vocci & Montoya, 2009)
Overall, behavioral therapies have shown positive results in promoting
methamphetamine abstinence during treatment, but do not produce lasting
changes

after

treatment.

This

suggests

that

other

strategies,

like

pharmacotherapy, are needed.
Pharmacotherapy
Methamphetamine belongs to a class of drugs called phenylethylamines and
is lipophilic, which allows it to readily cross the blood-brain barrier.
Methamphetamine increases the release of endogenous monoamines, primarily
dopamine, through different biological processes. First, methamphetamine is
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readily transported into the nerve terminal by diffusion across the cell membrane
and is also transported by catecholamine-uptake transporters. Once in the nerve
terminal, methamphetamine interacts with vesicular monoamine transporter-2
(VMAT-2) to redistribute monoamines from vesicles into the cytosol. Also,
methamphetamine

reverses

catecholamine-uptake

transporters

causing

monoamines that are free in the cytosol to be moved into the synapse. Finally,
methamphetamine inhibits the activity of monoamine oxidase, which breaks
down monoamines in the cell, and promotes tyrosine hydroxylase, which allows
for increased synthesis of dopamine (reviewed in Schep, Slaughter, & Beasley,
2010).
Based on this neuropharmacology, the dopamine system has been targeted
for

medications

development.

Both

antagonist

treatment

and

agonist

replacement have been tested (for reviews see Herin, Rush, & Grabowsi 2010;
Karila, Weinstein, Aubin, Benyamina, Reynaud, & Batki, 2010; Rush, Vansickel,
Lile, & Stoops, 2009). Antagonists block the effects of the abused drug to
extinguish self-administration. Agonist replacement produces cross tolerance to
the drug of abuse by diminishing the high that is achieved when the drug of
abuse is taken, which leads to extinction of drug taking (for reviews see Herin,
Rush, & Grabowsi 2010; Karila, Weinstein, Aubin, Benyamina, Reynaud, & Batki,
2010; Rush, Vansickel, Lile, & Stoops, 2009).
The first pharmacologic approach that was tested to treat methamphetamine
abuse was typical antipsychotics as an antagonist treatment. Dopamine is
thought to mediate the abuse of methamphetamine and typical antipsychotics are
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D2 antagonists, which should block methamphetamine from binding to dopamine
receptors. Pimozide is one example of an atypical antipsychotic that has been
tested (for review: Brauer, Goudie, & de Wit, 1997). Pimozide has been shown to
block the discriminative effects of 1 mg/kg amphetamine in amphetamine-trained
rats (Nielsen & Jepsen, 1985). Also, rats pretreated with pimozide selfadministered fewer doses of amphetamine and were slower to reinstate
responding after extinction compared to placebo treated animals (Yokel & Wise,
1976). In a study using dogs, pretreatment with pimozide increased
amphetamine self-administration, which has been linked to increased responding
for drug early in extinction models (Risner & Jones, 1976). However, pimozide
inconsistently blocked amphetamine discrimination in rhesus monkeys, with
some doses effective in a subset of the sample and other animals in the sample
displaying no effect of pimozide pretreatment. Additionally, because of a
decrease in the response rate when pimozide and amphetamine were combined,
higher doses were not tested (Kamien & Woolverton, 1989). In humans, results
have also been mixed. One study showed that 2 mg of pimozide blocked
increases in arousal after a 10 mg dose of d-amphetamine in healthy volunteers
(Silverstone, Fincham, Wells, & Kyriakides, 1980). However, in another study
with healthy volunteers, pretreatment with 1 or 2 mg pimozide had no effect on
10 or 20 mg doses of d-amphetamine (Brauer & de Wit, 1996). In a later study, a
higher dose of pimozide (8 mg) was tested in healthy volunteers and found that
pimozide had no effect on subjective effects after 10 or 20 mg of d-amphetamine.
Additionally, some side effects including sedation, agitation, restlessness, facial
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spasms, and rigidity were noted (Brauer & de Wit, 1997). Similar research has
been

done

with

other

typical

antipsychotics,

including

haloperidol,

chlorpromazine, and fluphenizine (for review see Brauer, Goudie, & de Wit, 1997;
Colpaert, Niemegeers, & Janssen, 1978; Schechter & Cook, 1975; Wilson &
Schuster, 1972; Arnt, 1996).
In response to the mixed results and side effects associated with typical
antipsychotics, atypical antipsychotics have been tested as a possible antagonist
treatment. Atypical antipsychotics, including risperidone and aripiprazole, were
considered as possible pharmacotherapies, because of their action on dopamine
and serotonin receptors. Risperidone is a dopamine and serotonin antagonist,
and it is believed that blocking monoamine binding through the use of an
antagonist may decrease the rewarding effects of methamphetamine (Fletcher,
1998; Grabowski, et al., 2000; Meert, Dr Haes, Vermote, & Janssen, 1990;
Meredith, et al., 2009; Rush, Stoops, Hays, Glaser, & Hays, 2003; Wachtel,
Ortengren, & de Wit, 2002). Preclinical experiments have shown that risperidone
reduced drug-appropriate responding to d-amphetamine in d-amphetamine
trained rats (Arnt, 1996; Meert, De Haes, Vermote, & Janssen, 1990) and selfadministration of d-amphetamine in rats (Fletcher, 1998). When tested in healthy
human volunteers, acute risperidone pretreatment did not significantly reduce
subject-rated drug-effects of methamphetamine, but did produce a trend toward
decreased subject-rated drug-effects (Wachtel, Ortengren, & de Wit, 2002). In
another study, healthy human volunteers trained to discriminate d-amphetamine
showed

that

pretreatment

with

risperidone
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decreased

drug-appropriate

responding to d-amphetamine and reduced subject-rated drug-effects of damphetamine. However, this study also showed some performance impairments
after risperidone pretreatment (Rush, Stoops, Hays, Glaser, & Hays, 2003). In an
open label clinical trial injectable risperidone was tested for the treatment of
methamphetamine dependence, only forty-four percent of all possible urine
samples were negative for methamphetamine, when analyzed using an intent-totreat model (Meredith, et al., 2009). Also, patients experienced negative sideeffects of risperidone including sedation, which occurred in eighty percent of
participants, and akathisia, which occurred approximately seventeen percent of
participants (Meredith, et al., 2009). A double-blind placebo-controlled trial was
designed to test varying doses of risperidone for the treatment of cocaine
dependence. Participants in the 8 mg risperidone condition had a greater
proportion of cocaine positive urine samples in the first month of the trial
compared to all of the other groups, including placebo (Grabowski, et al., 2000).
None of the participants randomized to the highest dose condition, 8 mg
risperidone, completed the study. Over all of the doses tested, risperidone
treatment did not improve outcomes or retention. Additionally, participants
experienced multiple negative side effects of the medication (Grabowski, et al.,
2000). The increase in positive urine screens, poor retention, and multiple
negative side effects suggest that risperidone is not likely to be an effective
pharmacotherapy as treatment retention and compliance may be problematic.
Aripiprazole, another atypical antipsychotic, which is a dopamine and
serotonin partial agonist, has also been tested as a potential pharmacotherapy
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for

methamphetamine

dependence.

Similar

to

risperidone,

aripiprazole

pretreatment showed promising results in healthy human volunteers (Sevak, et
al., 2011; Stoops, 2006). Clinical trials testing aripiprazole for methamphetamine
dependence have generally shown no significant reduction in methamphetamine
use (Coffin, et al., 2012; Tiihonen, et al., 2007). Additionally, one of the trials was
ended early when interim analysis showed that participants in the aripiprazole
arm of the study were more likely to submit a urine sample positive for
amphetamine than participants receiving placebo (Tiihonen, et al., 2007). This
increase in drug use in the aripiprazole condition is disconcerting and suggests
that antagonist treatment may not be an effective strategy for treating
methamphetamine abuse. These studies suggest that a different approach is
needed to identify a potential pharmacotherapy for treating methamphetamine
dependence.
Agonist replacement may be an alternative to antagonist treatment for
methamphetamine dependence. Dopamine agonists have been proposed as a
potential pharmacotherapy as they may increase extracellular dopamine, which
has been found to be depleted after long-term stimulant use, without the
rewarding properties produced by methamphetamine (reviewed in: Herin, Rush,
& Grabowski, 2010; Moeller, Schmitz, Herin, & Kjome, 2008). Agonist
replacement is commonly used for other types of substance use, including
methadone for opiate abuse and nicotine replacement for tobacco use. In
addition, dopamine agonists have shown promising results when tested for
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treating cocaine dependence (reviewed in: Herin, Rush, & Grabowski, 2010;
Moeller, Schmitz, Herin, & Kjome, 2008).
Few studies have been conducted to test agonist replacement with
methamphetamine. However there is an extensive literature related to agonist
replacement for treating cocaine dependence that may be germane to the
approach of using agonist replacement for methamphetamine abuse. Numerous
dopamine agonists have been tested for treating cocaine dependence including
d-amphetamine, which can provide translational evidence for the use of damphetamine for methamphetamine abuse. Preclinical studies with rats have
shown that chronic maintenance with d-amphetamine decreases cocaine taking
on a progressive-ratio schedule of self-administration (Chiodo & Roberts, 2009),
decreases breakpoints of responding for cocaine (Chiodo, Läck, Roberts, 2008),
and produces a rightward shift in the discrimination and self-administration
curves of cocaine (Peltier, Li, Lytle, Taylor, & Emmett-Oglesby, 1996). Similarly,
preclinical studies using rhesus monkeys have shown that chronic pretreatment
with d-amphetamine reduced self-administration of cocaine (Czoty, Gould,
Martelle, & Nader, 2011; Czoty, Martelle, & Nader, 2010; Foltin & Evans, 1998;
Negus & Mello, 2003a; Negus & Mello, 2003b). Human laboratory studies with
healthy non-treatment seeking cocaine users have shown that maintenance on
d-amphetamine reduced some of the positive subjective effects of intranasal
cocaine and decreased self-administration of 20 mg of cocaine (Rush, Stoops, &
Hays, 2009; Rush, Stoops, Sevak, & Hays, 2010). Finally, clinical trials have
shown positive results using d-amphetamine as a potential treatment for cocaine
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dependence (Grabowski, et al., 2001; Grabowski, et al., 2004; Shearer, Wodak,
van Beek, Mattick, & Lewis, 2003). Two clinical trials have shown decreases in
cocaine positive urine samples with an escalating dose of 30 mg to 60 mg damphetamine (Grabowski, et al., 2001; Grabowski, et al., 2004). Another clinical
trial tested 60 mg d-amphetamine and did not find a significant decrease in
positive urine samples, but participants in the treatment group reported
significantly less cocaine use and lower levels of craving compared to those
receiving placebo treatment (Shearer, Wodak, van Beek, Mattick, & Lewis,
2003). These findings provide evidence for the use d-amphetamine as a potential
pharmacotherapy for cocaine dependence, which may also translate to
methamphetamine dependence.
Similar to the findings with cocaine, dopamine agonists that have been tested
for

methamphetamine

pharmacotherapy,

with

dependence
fewer

and

unpleasant

show

promise

as

a

potential

side

effects

or

performance

impairments than other classes of medications that have been tested (Herin,
Rush, & Grabowsi, 2010; Karila, Weinstein, Aubin, Benyamina, Reynaud, &
Batki, 2010). A recent study tested subject-rated drug-effects of varying doses of
methamphetamine during d-amphetamine maintenance compared to placebo in
chronic stimulant abusing individuals. It was found that 45 mg/day damphetamine

reduced

subject-rated

drug-effects

of

methamphetamine

significantly compared to placebo (Rush, Stoops, Lile, Glaser, & Hays, 2011).
This

suggests

that

d-amphetamine

may

be

effective

for

treating

methamphetamine abuse, but this study did not test to see if d-amphetamine

10

would reduce self-administration of methamphetamine in a controlled laboratory
or clinical setting. One clinical trial showed that pretreatment with d-amphetamine
decreased illicit amphetamine use in intravenous drug users (Moeller, Schmitz,
Herin, & Kjome, 2008). Another clinical trial was designed to test the efficacy of
sustained release d-amphetamine for the treatment of methamphetamine abuse
in treatment seeking methamphetamine users. The data showed that treatment
with

60

mg

of

sustained-release

d-amphetamine

did

not

reduce

methamphetamine use compared to placebo maintenance (Galloway, et al.,
2011). Similarly, another clinical trial demonstrated that maintenance on 110 mg
d-amphetamine for the treatment of methamphetamine did not reduce
methamphetamine abuse compared to placebo maintenance (Longo, et al.,
2009). The results from clinical trials are mixed, which along with a promising
signal from the human laboratory, suggests that more research is needed to
determine if d-amphetamine may be an effective pharmacotherapy for
methamphetamine abuse.
Overall, a universally effective pharmacotherapy for methamphetamine abuse
has not been identified. While there has not been much work done testing
agonist replacement as a pharmacotherapy for methamphetamine, previous work
shows a good signal that agonist replacement may be effective and so far
agonist replacement has shown the best signal as a pharmacotherapy for
cocaine dependence. These findings suggest that more work is needed to test
agonist replacement for methamphetamine dependence.
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Cognitive Impairment as a Target for Medications Development
A recent target for medication development is the remediation of cognitive
deficits related to chronic stimulant abuse. This has stemmed from studies that
have associated poorer treatment outcomes and early treatment drop-out with
performance on various measures of cognitive functioning (Ahronovich, Hasin,
Brooks, Liu, Bisaga, & Nunes, 2006; Ahronovich, Nunes, & Hasin, 2003; Brewer,
Worhunsky, Carroll, Rounsville, & Potenza, 2008; Hester, Lee, Pennay, Nielson,
& Ferris, 2010; Moeller, Dougherty, Barratt, Schmitz, Swann, & Grabowski, 2001;
Turner, LaRowe, Horner, Herron, & Malcolm, 2009).
The cocaine Stroop task assesses for a bias toward drug related stimuli by
recording the reaction time for participants to respond to the color of both neutral
and drug related words. The cocaine Stroop has consistently shown that chronic
stimulant using individuals show an attention bias toward salient (i.e., drug
related) words (Brewer, Worhunky, Carroll, Rounsaville, & Potenza, 2008;
Gardini, Caffarra, & Venneri, 2009; Hester, Lee, Pennay, Nielson, & Ferris, 2010;
Liu, Lane, Schmitz, Waters, Cunningham, & Moeller, 2011; Sharma & Money,
2010). There is an inverse relationship between performance on the cocaine
Stroop and treatment retention, such that a higher attention bias is associated
with less time in treatment (Brewer, Worhunsky, Carroll, Rounsaville, & Potenza,
2008; Hester, Lee, Pennay, Nielson, & Ferris, 2010).
Other studies have investigated impulsivity in stimulant users, as individuals
who are more impulsive may choose short-term reinforcement from using a drug
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as opposed to longer-term reinforcement associated with abstinence. These
studies have found that chronic stimulant users tend to be more impulsive
compared to controls on the Barratt Impulsiveness Scale and tend to choose less
advantageous decks on the Iowa Gambling Task (Kjome et al., 2010; Moeller,
Dougherty, Barratt, Schmitz, Swann, & Grabowski, 2001).
Cognitive performance on a battery of tests has also been assessed as part
of two clinical trails. These studies showed differences in cognitive performance
of treatment completers compared to dropouts, with dropouts displaying
significantly poorer performance on measures of attention, memory, spatial ability
and processing, and mental reasoning (Ahronovich, Hasin, Brooks, Liu, Bisaga,
& Nunes, 2006; Ahronovich, Nunes, & Hasin, 2003).
Further research is needed to assess different domains of cognitive function
to see if deficits can be identified. Additionally, research has not yet been done to
determine if cognitive performance of stimulant users can be improved using
pharmacological methods.
Summary
Methamphetamine abuse is a significant problem in the United States, with
over

four

hundred

thousand

people

reporting

past

month

use

of

methamphetamine and increasing numbers of people initiating use (SAMHSA,
2012). Also, methamphetamine abuse is associated with a very high cost to
society (Nicosia, Pacula, Kilmer, Lundberg, & Chiesa, 2009). Behavioral
therapies, especially contingency management, have shown some potential as a
treatment for methamphetamine abuse. However, differences in use observed
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between treatment groups and either treatment as usual or no treatment do not
always persist at follow-up (for review see: Lee & Rawson, 2008 and Roll, 2007;
Vocci & Montoya, 2009; Rebak, Peck, Dierst-Davies, Nuno. Kamien, & Amass,
2010; Roll, et al., 2006). It is possible that behavioral therapies combined with
pharmacotherapy could produce more robust patterns of abstinence, but an
effective pharmacotherapy has yet to be identified. Studies testing damphetamine as a potential pharmacotherapy for methamphetamine abuse have
shown decreases in illicit stimulant abuse in intravenous amphetamine users and
decreases in subject-rated drug-effects after methamphetamine administration
(Moeller, Schmitz, Herin, & Kjome, 2008; Rush, Stoops, Lile, Glaser, & Hays,
2011, respectively). However, a clinical trial testing d-amphetamine as a
treatment for methamphetamine abuse in treatment seeking methamphetamine
users did not show a reduction in methamphetamine use compared to placebo
(Galloway, et al., 2011). Finally, remediation of cognitive deficits associated with
chronic stimulant abuse have become a target for medications development,
since recent studies have shown that poor performance on cognitive measures
are associated with poor treatment outcomes and retention (Ahronovich, Hasin,
Brooks, Liu, Bisaga, & Nunes, 2006; Ahronovich, Nunes, & Hasin, 2003; Brewer,
Worhunsky, Carroll, Rounsville, & Potenza, 2008; Hester, Lee, Pennay, Nielson,
& Ferris, 2010; Moeller, Dougherty, Barratt, Schmitz, Swann, & Grabowski, 2001;
Turner, LaRowe, Horner, Herron, & Malcolm, 2009). It is likely that a successful
methamphetamine intervention will need to encompass each of these
approaches.
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Chapter Two. Purpose of Project
The aim of the present study was to evaluate d-amphetamine as a potential
pharmacotherapy for methamphetamine abuse. This was accomplished by
examining

the

subject-rated

drug

effects,

self-administration,

cognitive

performance, and physiological measures after the administration of varying
doses

of

methamphetamine

during

chronic maintenance

on

either d-

amphetamine or placebo. These measures have previously been shown to be
sensitive to the effects of methamphetamine (Lile, Stoops, Glaser, Hays, & Rush,
2011; Rush, Stoops, Lile, Glaser, & Hays, 2011; Sevak, Stoops, Hays, & Rush,
2009; Sevak, Vansickel, Stoops, Glaser, Hays, & Rush, 2011).
Chapter Three. Hypothesis
Behavioral
Methamphetamine will be self-administered by participants more than
placebo. During d-amphetamine maintenance, participants will self-administer
fewer

doses

of

methamphetamine

than

during

placebo

maintenance.

Methamphetamine administered alone will dose dependently increase positive
subject-rated drug-effects (e.g., Like Drug; Willing to Take Again). During damphetamine maintenance, participants will report lower levels of drug-effects
compared to placebo maintenance.
Cognitive
d-Amphetamine

maintenance.

d-Amphetamine

alone

will

improve

participants’ performance on the cognitive battery compared to placebo
maintenance.
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Methamphetamine challenge. Methamphetamine administered alone and in
combination with d-amphetamine will dose-dependently improve participants’
performance on the cognitive battery compared to performance after placebo
administration.

d-Amphetamine

maintenance

will

attenuate

impairments

observed after methamphetamine administration.
Physiological
Methamphetamine will dose dependently increase heart rate and blood
pressure. d-Amphetamine, when administered alone, will increase physiological
measures.

Administration

of

methamphetamine

during

d-amphetamine

maintenance will increase heart rate and blood pressure, but will be safe and
well-tolerated.
Chapter Four. Method
The proposed experiment and informed consent document were approved by
the Institutional Review Board of the University of Kentucky Medical Center.
Participants
Eight participants who reported stimulant dependence were recruited through
the use of flyers, newspaper, online and radio ads, and by word of mouth for
participation in this experiment. Prior to enrollment in the experimental protocol,
all participants were screened using health-history, drug-use history, and
psychiatric history questionnaires. Questionnaires included: the Beck Depression
Inventory (BDI), Brief Symptom Index (BSI), assessments for attention deficit
hyperactivity disorder (ADHD), mental status, and drug and alcohol dependence.
Drug histories were collected including time since first use, frequency and
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quantity of use, and drugs used over the lifetime. Laboratory values were
collected for all participants, including a complete blood count and chemistry
panel, urinalysis, and electrocardiogram (ECG). Laboratory values outside of the
normal range were reviewed by Dr. Lon R. Hays (University of Kentucky,
Department of Psychiatry) or Dr. Paul E. A. Glaser (University of Kentucky,
Department of Psychiatry) to determine if the levels were clinically significant
before admittance into the study. ECGs were interpreted by Dr. John Gurley
(University of Kentucky, Department of Cardiology) and any participant with an
ECG determined to be abnormal was excluded from participation from the study.
Participants with a history of clinically significant medical conditions, CNS
disorders, impaired heart functions, history of chronic pulmonary obstructive
disease, history of seizures, family history of sudden death, or any
contraindications to the administration of stimulant medications (e.g. allergic
reaction to stimulant medications or heart problems) were excluded from
participation. Also, participants with a current or past history of psychiatric illness
that in the opinion of the study physicians would interfere with performance were
excluded from participation. All participants were physically and psychologically
healthy, as determined by the medical staff, and were within 20% of their ideal
body weight (BMI tables).
Payment and Follow-Up
Participants earned $80 for each experimental session, with $40 being paid
for each session completed and $40 paid as a bonus if all sessions were
completed. Participants also had the opportunity to earn approximately $6 on the
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Balloon Analog Risk Task (BART) completed twice on each cognitive testing day
and once during each experimental session (shown in Tables 1 and 2). In total,
participants were able to earn approximately $2000. At the end of their
participation, participants returned to the Laboratory of Human Behavioral
Pharmacology (LHBP) and received a check for up to $500 once per week until
they were paid all of the money they earned. When participants received their
weekly payments, they also completed a brief follow-up to assess recent drug
use. These data were not analyzed as part of the proposed study, but were
collected in case future analyses look for changes in drug use after enrollment in
a study. During this assessment, participants provided an expired breath sample
to test for the presence of alcohol as well as provided a urine sample to test for
the presence of illicit substances.
General Procedures
Prior to admission to the Clinical Research Development and Operations
Center (CR-DOC) and before all study sessions (cognitive and experimental),
participants provided a urine sample that was tested for the presence of drugs of
abuse. Urine samples were tested using the Integrated E-Z Split Key Cup
(Iminia, Los Angeles, CA) and Fastect Drug Screen Dipstick Test MTH 300 and
OXY 100 (Branan Medical Corp., Irvine, CA) to test for the presence of
amphetamines,

barbiturates,

benzodiazepines,

cocaine,

methadone,

methamphetamine, opiates, oxycodone, PCP, and THC. Participants who
provided a urine sample positive for drugs other than cocaine or THC were not
admitted at that time. On session days, urine samples could test positive for
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THC, amphetamines, or methamphetamine, depending on marijuana use prior to
admittance or drugs administered during study sessions on previous days and
were evaluated by Dr. William Stoops to determine if the study session could
continue as planned. Any participant, who provided a urine sample that tested
positive for a drug that was not administered as part of the study protocol, was
discharged from the study. Expired breath samples were collected to assess for
the presence of alcohol using a hand-held Alcosensor (Intoximeters, St. Loius,
MO). Also, participants were asked to complete a sobriety test and participants
who passed the sobriety test were allowed to participate in the day’s session.
Female participants were required to use an effective form of birth control
prior to admittance to the CR-DOC and received a pregnancy test using a urine
HCG test (confirms II, I.M. Isbell Marthé Diagnostics, Inc., Naples, FL) prior to
admittance to the CR-DOC as well as before every study session. Any female
participant who tested positive for pregnancy was discharged from the study.
Participants resided at the CR-DOC for approximately 28 days and completed
one practice and eight experimental sessions. Participants had a full day to
acclimate prior to beginning maintenance medications. Timeline for maintenance
medications and sessions are shown in Table 1. Participants were informed that
during the study they would be given medications that may be placebo or an FDA
approved prescription stimulant, such as d-amphetamine or methamphetamine.
Participants were informed that the purpose of the study was to see how the
drugs affect mood and behavior, if they like the drug and would be willing to take
it again, and the affect of the drugs on cognitive and performance tasks.
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Participants were not informed of the specific drugs they received, possible
outcomes, or performance expectations.
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Table 1. Timeline for maintenance medications and sessions
Day 1

Admission to CR-DOC

Day 2

Practice Session

Days 3-24

Drug maintenance. Doses administered at 0700 and 1900
daily

Day 9

Cognitive and performance task battery completed twice

Days 10-13

Experimental Sessions (timeline shown in Table 2)

Day 20

Cognitive and performance task battery completed twice

Days 21-24

Experimental Sessions (timeline shown in Table 2)

Day 25

Discharge
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Practice session. Participants completed a practice session prior to beginning
maintenance medication to familiarize them with the behavioral tasks,
progressive ratio, and timeline of experimental sessions, which are described
below. No medications were administered during the practice session.
Instructions for practice session. Today, you will not receive any medications,
but will periodically complete behavioral tasks to familiarize you with the study
routine. One of these tasks will be the progressive ratio task that you will do in
experimental sessions to earn drug. The number of responses required for
completing each of the opportunities to earn drug will increase as you
proceed in the task. You will have to complete the full task today. In the
future, you will decide how much of the task you want to complete to earn
intranasal drug.
Experimental sessions. Participants completed four experimental sessions
after at least 7 days of maintenance in each maintenance condition. Participants
completed a pre-session task at 0900 and at 0930 sampled intranasally the
medication that they had the opportunity to work for later in the session.
Participants completed subject-rated drug-effects questionnaires at 0945 and
1000. Between 1005 and 1100, participants completed an abbreviated cognitive
battery (visual probe, cued go/no-go, and BART). Then participants completed
the subject-rated drug-effects questionnaires again at 1100 and 1130, followed
by a break from 1145 until 1330. During the break, participants were allowed to
eat lunch and engage in any desired activities, except smoking. At 1330
participants’ vitals were recorded and the self-administration portion of the

22

session began. Between 1345 and 1430 participants completed the progressive
ratio and subject-rated drug-effects questionnaires. At 1430 the participants
received the dose that they worked for in the progressive ratio and completed
subject-rated drug-effect questionnaires every 15 minutes for the next hour. After
1530, participants completed the subject-rated drug-effect questionnaires every
30 minutes for another hour. A timeline of experimental sessions is illustrated in
Table 2. It is possible that two participants were enrolled in the study
simultaneously and participants were instructed not to discuss drug effects with
any other participants.
Instructions for medication-administration during sampling. You will now
receive a drug. Please pay attention to how the drug makes you feel, because
later today you will be given the opportunity to earn all, some or none of this
drug. The drug will be in the form of a powder. Please follow along with the
research assistant as he/she reads the instructions for you for preparing the
powdered medication.
1) The nurse will empty the powdered medication on the mirror for you.
2) With the single-edged razor blade, please separate the powdered medication
into two (2) lines that are approximately equal in volume.
3) When told to do so by the research assistant and nurse, please use the straw
to inhale or snort one of the “lines” into each of your nostrils.
4) You will have a total of two (2) minutes to inhale or snort the drug.
Instructions for medication administration during self-administration. You will
now have the opportunity to work for the drug you sampled this morning.
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Please refer to your notes about the drug effects from the previous session
because today you will be able to work for all, or some, of the drug from this
morning.
You will have a total of ten (10) opportunities to respond by clicking on a
mouse to receive the drug from this morning, and can earn the full dose from
this morning’s session. As you complete each segment, you will earn 1/10th of
the drug. The total amount of drug that you earn today will be given to you all
at once when you are done.
You should understand that you do not have to work for any drug today.
However, if you choose not to work for any drug, you will not receive any drug
today. You should also understand that you can stop working at any time.
However, if you start a segment on the computer and do not finish it, you will
only receive the total drug that you earned by completing earlier segments.
Whether or not you choose to work for drug, you will have to complete the
rest of the 3-hour session.
Baseline cognitive testing. Participants completed a baseline testing session,
which served as a practice session to familiarize them with the battery of
cognitive and performance tasks that were administered during the maintenance
cognitive testing days. Baseline study sessions followed the same timeline and
procedures as the maintenance cognitive testing days, except they were
conducted at the Laboratory of Human Behavioral Pharmacology, rather than the
CR-DOC inpatient unit. No medications were administered.
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Maintenance cognitive testing. Participants completed the cognitive battery at
0830 and 1300 or 1000 and 1430, with the participant completing the battery at
the same pairing of times on each testing day. Maintenance testing was
conducted on the last day of maintenance before study sessions began for each
maintenance condition (0 mg d-amphetamine and 40 mg d-amphetamine). The
cognitive battery consisted of the grooved pegboard task, visual probe task, cued
go/no-go task, n-back, cocaine Stroop task, balloon analog risk task (BART), and
digit

symbol

substitution
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task

(DSST).

Table 2. Experimental Session Timeline
0830

Vitals, sobriety test, pre-session paperwork completed

0900

Pre-session subject-rated drug-effects, vitals recorded

0930

Sample dose administered, subject-rated drug-effects, vitals
recorded

0945

Subject-rated drug-effects, vitals recorded

1000

Subject-rated drug-effects, vitals recorded

1005

Abbreviated cognitive battery, vitals recorded after each task

1100

Subject-rated drug-effects, vitals recorded

1130

Subject-rated drug-effects, vitals recorded

1145

Participant had a 2 hour break

1330

Vitals recorded

1345

Progressive ratio, pre-dose subject-rated drug-effects, vitals
recorded

1430

Dose administered, subject-rated drug-effects, vitals recorded

1445

Subject-rated drug-effects, vitals recorded

1500

Subject-rated drug-effects, vitals recorded

1515

Subject-rated drug-effects, vitals recorded

1530

Subject-rated drug-effects, vitals recorded

1600

Subject-rated drug-effects, vitals recorded

1630

Subject-rated drug-effects, vitals recorded
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Modified Progressive-Ratio Procedure
The modified progressive-ratio procedure has been used in previous studies
and has been shown to be a reliable measure of human drug reinforcement
(Comer, Collins, & Fischman, 1997; Comer, Collins, MacArthur, Fischman, 1999;
Comer, Collins, Wilson, Donovan, Foltin, & Fischman, 1998; Rush, Essman,
Simpson, & Baker, 2001; Stoops, 2008). During the self-administration portion of
each experimental session participants had 10 opportunities to work to earn a
portion of the drug sampled that morning. Participants were presented with the
progressive-ratio task on a computer screen and they were instructed to use the
computer mouse to click on a button to work to earn a portion of the drug, each
completed ratio earned 1/10th of the sampled dose. Participants were instructed
that they might choose to work to earn all, a portion of, or none of the sampled
dose. To complete the first ratio, participants were required to click 400 times and
each additional ratio increased by 100 (i.e. 500, 600, 700, 800, 900, 1000, 1100,
1200, and 1300). To earn all of the sampled dose, participants were required to
click a total of 8500 times. The participant was allowed quit the task at any time if
they clicked a button labeled stop and the task was terminated. They received
the dose for the highest ratio that was completed. This was verified by a research
assistant in the data file for the task. Data was collected on the breakpoint (i.e.
the highest ratio that was completed).
For each ratio completed the participant earned 1/10th of the drug that was
sampled that morning. The doses of methamphetamine were mixed with lactose
monohydrate powder, N.F. so that all doses were 60 mg of powder. After taking
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the self-administered dose intranasally, participants completed the subject-rated
drug-effect questionnaires every 15 minutes for the first hour then every 30
minutes for another hour. If the participant chose not to work for any of the
sampled dose they still completed the scheduled tasks, which eliminated the
possibility of a participant choosing no drug to end a session early. All sessions
were conducted as shown in Table 1, regardless of the drug dose earned.
Subject-Rated Drug-Effect Questionnaires
All of the subject-rated drug-effect questionnaires were administered using an
Apple microcomputer with a mouse attached in a fixed order. Participants
completed the tasks as indicated on the daily schedule in Table 1 during
experimental sessions.
Adjective Rating Scale. The adjective rating scale is a measure that consists
of 32 questions divided into two subscales: sedative and stimulant. Participants
were shown questions on a computer screen and were asked to indicate their
answer by using a computer mouse to select one of 5 buttons: “not at all,” “A little
bit,” “moderately,” “quite a bit,” or “extremely” (scored as 0-4 respectively). The
sedative subscale consists of the following adjectives: Clumsy, Dizzy, Confused,
Dazed, Sleepy, Depressed, Difficulty Walking, Drowsy, Nausea, Drunk, Fatigued,
Lazy, Relaxed, Tired, Sluggish, and Spaced Out.

The stimulant subscale

consists of the following adjectives: Active, Alert, Irregular Heartbeat, Good
Mood, Muscles Twitching, Agitated, Energetic, Excited, Euphoric, Irritable,
Nervous, Restless, Shaky, Sweaty, Talkative, and Heart Racing. Composite
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scores were produced for each subscale, with a maximum score of 64 on each
subscale.
Visual Analog Scale (True/False). The Visual Analog Scale (VAS) True/False
is a measure of subject-rated drug-effects. Participants were presented with
statements and a sliding scale that is 101 mm long on a computer screen. The
sliding scale was labeled “false” on the left and “true” on the right and participants
were asked to indicate how much they agree with the statement presented by
using a computer mouse to place a marker on the scale. Each item was scored
as how many millimeters the participant placed the marker from the end of the
scale indicating false (i.e. “false” would be scored as 0 and “true” would be
scored as 100). The maximum possible score was 100 for any item. The
statements presented were as follows: “Is the drug producing any effect right
now?; Is the drug producing any bad effects right now?; Is the drug producing
any good effects right now?; Is the drug making you feel high right now?; Are you
experiencing a rush from the drug right now?; How much do you like the drug
right now?; Is the drug making you feel stimulated right now?; Is the drug
impairing your performance right now?; Is the drug improving your performance
right now?; Based on how the drug effect feels right now, would you be willing to
take this drug again?; Based on how the drug effect feels right now, would you
be willing to pay for this drug?; Is the drug making you feel active, alert or
energetic right now?; Is the drug making you feel shaky or jittery right now?; Is
the drug making you feel euphoric right now?; Is the drug making you experience
an irregular or racing heartbeat right now?; Is the drug making you feel talkative
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or friendly right now?; Is the drug making you feel nauseous, queasy, or sick to
your stomach right now?; Is the drug making you feel nervous or anxious right
now?; Is the drug making you feel restless right now?; Is the drug making you
feel sluggish, fatigued or lazy right now?
Cognitive and Performance Measures
The cognitive measures were administered using the grooved pegboard, a
Dell laptop computer (visual probe, cued go/no-go, n-back, cocaine Stroop, and
BART), and an Apple Macintosh microcomputer (DSST) in a fixed-order. These
measures were administered twice daily on cognitive testing sessions and an
abbreviated battery (i.e. visual probe, cued go/no-go, and BART) was
administered once during experimental sessions. These tasks have been
validated and used in previous studies (Brewer, Worhunsky, Carroll, Rounsaville,
& Potenza, 2008; Gardini, Caffarra, & Venneri, 2009; Hester, Dixon, & Garavan,
2006; Kaufman, Ross, Stein, & Garavan, 2003; Lejuez, et al., 2002; Liu, Lane,
Schmitz, Waters, Cunningham, & Moeller, 2011; MacLeod, Mathews, & Tata,
1986; Oliveria, Barroso, Silveira, Ponce, Vaz, & Nappo, 2009; Waters, Sayette,
Franken, & Schwartz, 2005).
Grooved Pegboard Task. The grooved pegboard task was an assessment of
manual dexterity (Trites, 1977). Participants were presented with a pegboard that
consists of a dish to hold the pegs, enough pegs to fill the pegboard with some
extra, and a pegboard with 25 holes with the pegs oriented in varying directions.
Participants were asked to use only their dominant hand and place the pegs into
the pegboard as quickly as they could. Data was collected as a composite of the
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number of holes filled on the pegboard, time to complete the task in seconds,
and number of pegs dropped.
Instructions for the grooved pegboard task. This is a pegboard and these are
the pegs.
All the pegs are the same. They have a groove, that is, a round side and a
square side and so do the holes in the board. What you must do is match the
groove of the peg with the groove of the board and put these pegs into the
holes like this. (Demonstrate by filling the first row, then remove the pegs and
return them to the tray)
When I say go, begin here and put the pegs in the boards as fast as you can
using only your dominant hand. Fill the top row completely from (right handed:
left to right or left handed: right to left). Do not skip any: fill each row the same
way you filled the top row. Any questions? Ready, as fast as you can, go.
Visual Probe Paradigm. The visual probe paradigm measured attention bias
toward salient images, such as images of a drug of abuse (MacLeod, Mathews,
& Tata, 1986). Participants were presented pairs of images, either a cocaine
image and a neutral image or two neutral images, oriented with one on the right
side of the computer screen and one on the left. After a set period of time, the
images disappeared and a target replaced one of the images. Participants were
asked to identify which side of the screen the target appeared on by responding
on one of two keys on a computer keyboard. Data were collected on reaction
times when the target replaced a cocaine image and when the target replaced a
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neutral image and the attention bias score was obtained by subtracting reaction
times to cocaine images from reaction times to neutral images.
Instructions for the visual probe task. This is a reaction task. You will be
presented with a fixation point (a tiny cross) at the center of the screen
followed by a pair of images. These are images of various objects. Again,
you are to look at the pictures while they are on the screen. Once the images
disappear from the screen, an X will appear on either the left or right side of
the screen.

Your task is to respond as quickly as possible to the X by

pressing the yellow key if the X is on the left side of the screen or the green
key if the X is on the right side of the screen. Once you make your response,
another fixation point will appear followed by the presentation of a new set of
images. You will perform several of these trials.
Cued Go/No-Go Task. The cued go/no-go task was a measure of inhibitory
control (Miller, Schaffer, & Hackley, 1991). Participants were shown a cue, an
outline of a rectangle, which was oriented either horizontally or vertically. The
orientation of the rectangle signified it as a go or a no-go cue. Participants were
asked to respond on a computer keyboard when the rectangle filled in green, but
to inhibit responding when the rectangle filled in blue. For example, when a
vertical rectangle was a go cue, 80% of the time it filled in green, which indicated
to the participant that they should respond. However, 20% of the time go cues
filled in blue, which required participants to inhibit responding after being primed
to respond. Data were collected on the percent of responses that were correctly
inhibited after being presented with a go cue.
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Instructions for the cued go/no-go task. This is a reaction time task that I
would like you to perform. While you are performing the task you sit in front of
the computer screen just you as are doing. You place your index finger on the
‘?’ key.
Presented on the screen will be rectangular boxes that are standing upright or
lying flat.
The boxes are empty when they first appear on the screen. If the box turns
green then you are to press the ‘?’ button as quickly as possible. If the box
turns blue then no response is required.
Now, before a box appears, you will see a plus sign in the middle of the
screen. It serves as a fixation point so that you know where to focus your
attention on the computer screen. After the plus sign disappears, a box will
appear on the screen. Again, if the box turns green, respond as quickly as
possible by pressing the ‘?’ key. If the box turns blue then no response is
required.
To help you respond quickly, the computer will display how fast you are
pressing the key when the green target appears. Once you respond to a
green target, the screen will show the amount of time it took for you to make
that response.

The time is presented in milliseconds.

The fewer the

milliseconds, the faster the response. So lower numbers are better. If you
accidentally respond to a blue target, the screen will say “Incorrect
Response”.
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N-Back Task. The N-Back task assessed working memory by asking
participants to identify if letters presented on a computer screen were the same
or different than previous letters in a specific pattern (Kirchner, 1958). The task
consisted of three pattern conditions: one back, two back, and three back. In one
back, participants were asked to respond to each letter presented on the
computer screen to identify if it was the same as the letter immediately before the
letter presented or not the same. Two back required participants to respond if the
current letter was the same as or different than the letter presented two letters
before. Finally, the three back required participants respond to identify if the
current letter was the same as or different than the letter presented three letters
before. Data was collected on reaction time and accuracy to letters that are
targets (i.e. the same as) and not-targets (i.e. different than) for each of the
conditions.
Instructions for the n-back task. You will see letters on the screen, one letter
at a time.
When the letter on-screen matches the last letter presented (two letters back
for two back or three letters back for three back), press TARGET (1).
When the letter on-screen is not the same as the letter that came before it,
press NOT A TARGET (2).
Cocaine Stroop Task. The cocaine Stroop task was a modified version of the
Stroop task, which required participants to identify the color of cocaine words and
neutral words (Hester, Dixon, & Garavan, 2006; Liu, Lane, Schmitz, Waters,
Cunningham, & Moeller, 2011). Participants were presented words that are either
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blue, red, or green and they were asked to identify the color of the text by
pressing a key on a computer keyboard. Data were collected on the reaction time
to respond to neutral and cocaine words and an attention bias score was
obtained by subtracting the reaction time to cocaine words from the reaction time
to neutral words.
Instructions for the cocaine Stroop task. In this task you will be presented with
words that are either red, blue, or green. You will be asked to respond on the
keyboard with the color that the word is written in.
For red text respond with the number 1 (red dot)
For blue text respond with the number 2 (blue dot)
For green text respond with the number 3 (green dot)
Balloon Analog Risk task. The balloon analog risk task (BART) was a
measure of risk taking (Lejuez et al., 2002). Participants were presented with a
screen where they can click a computer mouse to pump a balloon, each trial
consisted of 20 balloons and each pump was worth $0.01. Each time the
participant clicked the mouse, $0.01 was added to a temporary bank, and at any
time participants may choose to end a balloon and save their earnings in a
permanent bank, which was paid to them at the end of the session. Participants
were instructed that they could pump the balloon as many times as they chose,
but that the balloon may pop after as few as one or two clicks or could fill the
screen, and if the balloon pops they lose all of the money stored in their
temporary bank. Data were collected on the percentage of balloons that pop.
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Instructions for the balloon analog risk task. Now you are going to see 20
balloons, one after another, on the screen. For each balloon, you will use the
mouse to click on the box that will pump up the balloon. Each click on the
mouse pumps the balloon up a little more.
BUT remember, balloons pop if you pump them up too much. It is up to you to
decide how much to pump up each balloon. Some of these balloons might
pop after just one pump. Others might not pop until they fill the whole screen.
You get MONEY for every pump. Each pump earns 1 cent(s). But if a balloon
pops, you lose the money you earned on that balloon. To keep the money
from a balloon, stop pumping before it pops and click on the box labelled
“Collect $$$”.
After each time you collect $$$ or pop a balloon, a new balloon will appear.
At the end of the experiment, you will be paid the amount earned on the
game.
Digit-Symbol Substitution Task (DSST). A computerized version of the DSST
was used in this experiment (McLeod, Griffiths, Bigelow, & Yingling, 1982).
Participants used a numeric keypad to reproduce patterns that were associated
with one of nine patterns associated with numbers shown on the computer
screen. Participants had 90 seconds to enter as many patterns as possible. Data
were collected on the number of patterns attempted and number of patterns
correctly entered.
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Physiological Measures
Heart rate, blood pressure, temperature, and heart rhythmicity (via ECG)
were measured using a Dinamap digital monitor (Critikon, Pro 1000, Tampa, FL).
Vitals were collected during experimental sessions every 30 minutes for 1.5
hours before medication administration starting at 0830 and then every 15
minutes until the participant went on break at 1145. After the break, vitals were
recorded at 1330, 1345, and 1430 followed by the self-administered dose. Vitals
were then recorded every 15 minutes until 1530 and after that they were
recorded every 30 minutes until 1630.
Drug Administration
All medications were administered in a double blind fashion, such that the
nurses, research assistant, and participant were not aware of the dose that is
being given. Dr. Stoops determined the dose order so that the nurse and
research assistant were not aware of the dose order. Maintenance medications
were prepared by over-encapsulating a commercially available 5 mg damphetamine spansule and loose filling the capsule with lactose monohydrate
powder, N.F. Participants received escalating doses of sustained release damphetamine twice daily until the target dose of 40 mg per day is reached.
Participants received 5 mg twice daily on the first day of d-amphetamine
maintenance, 10 mg twice daily on the second and third days, and 20 mg twice
daily for the remaining days. Placebo capsules were prepared in the same way
as the d-amphetamine, except only contained lactose monohydrate powder, N.F.
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Methamphetamine doses were prepared by weighing out the appropriate
dose (0, 10, 20 or 30 mg) of methamphetamine and then were mixed with lactose
monohydrate powder, N.F. to make a total of 60 mg of powder. Participants
sampled the entire dose in the morning the session and had the opportunity to
work for a portion of the sampled dose in the afternoon self-administration portion
of the session. Sampled doses were divided into 10 parts for self-administration
and were prepared into 10 vials that contained each of the possible doses that
the participant may earn (i.e., 10% to 100% of the sampled dose). Each of the
vials contained the appropriate tenth of methamphetamine powder and were
mixed with lactose monohydrate powder, N.F. so that all doses consisted of 60
mg of powder, regardless of the weight of methamphetamine.
Data Analysis
Statistical analysis was used to investigate drug effects on progressive-ratio
task, subject-rated drug-effects questionnaires, performance tasks, cognitive
tasks, and physiological indices. For all statistical analyses, effects with p ! .05
were considered significant.
Progressive ratio. Data from the progressive-ratio task were analyzed using a
two-factor repeated-measures analysis of variance (ANOVA). The factors were
d-Amphetamine (i.e., 0 or 40 mg/day) and Methamphetamine (i.e., 0, 10, 20, and
30 mg). F statistics were used to interpret the ANOVA outcomes. During selfadministration sessions, participants determined the amount of drug that they
ingested. Thus, varying amounts of drug was administered to participants during
the self-administration session. Due to participants ingesting varying amounts of
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drug,

data

from

subject-rated

drug-effects

questionnaires,

performance

measures, and physiological indices were not statistically analyzed.
Subject-rated drug-effects and physiological indices. Two analyses were
conducted to analyze subject-rated drug-effect and physiological data. First,
peak-effect data, which is the maximum response reported during data collection
for that session, were calculated for each participant. Second, data were
analyzed as area-under-the-time-action curve (AUC), which was calculated for
each participant using the trapezoidal method. Peak effect and AUC were
analyzed in the same fashion as breakpoint data from the progressive ratio task.
Cognitive Performance During Methamphetamine Challenge. Cognitive data
collected during experimental sessions were analyzed in the same fashion as the
break-point data.
Cognitive Performance During Maintenance. Cognitive data collected from
each of the tasks, excluding the N-Back Task, during each of the maintenance
conditions were analyzed using a t-test to compare placebo and d-amphetamine
(40 mg/day). For these analyses, the data were averaged across time (i.e.,
morning and afternoon). The N-Back Task was analyzed using a three-factor
repeated-measures ANOVA with d-Amphetamine (i.e., 0 or 40 mg/day), Time
(i.e., morning or afternoon), and Trial (i.e., one-, two-, or three-back) as factors.
Power Analysis
In a previous study from our laboratory, we assessed cocaine choice during
d-amphetamine and placebo maintenance (Rush et al., 2010). During damphetamine maintenance, subjects made significantly fewer choices for 20 mg
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intranasal cocaine relative to placebo maintenance. That study enrolled 9
subjects, which was sufficient to detect the small effect size (f=0.16) for damphetamine to reduce the reinforcing effects of cocaine. Enrolling a similar
number of subjects (n=8) was estimated to provide us with sufficient power to
detect a significant effect of d-amphetamine on methamphetamine choice, which
was the primary outcome variable for this study.
Chapter Five. Results
Methamphetamine Self-Administration During d-Amphetamine Maintenance
Progressive-Ratio Responding. ANOVA revealed a significant main effect of
methamphetamine on number of doses earned. Methamphetamine dosedependently increased the number of doses earned regardless of the
maintenance condition (Figure 1). There were no other significant effects on
number of doses earned.
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Figure 1.
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Subject-Rated Effects of Methamphetamine During d-Amphetamine
Maintenance
Adjective Rating Scale
Peak Effect. ANOVA revealed only a main effect of methamphetamine for
scores on the Stimulant scale of the Adjective Rating Scale. Methamphetamine
increased these scores as function of dose regardless of the maintenance
condition. There were no significant effects on the Sedative scale of the Adjective
Rating Scale. F-values and means are shown in Tables 3 and 4, respectively.
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Table 3. F-values from peak-effect analysis for physiological indices and subjectrated drug-effects measures (Bold indicates a significant F-value).
Outcome
Measures
Physiological
Diastolic Pressure
Heart Rate
Mean Arterial Pressure
Systolic Pressure
Temperature

d-AMPH

METH

METH x
d-AMPH

1.8
1.8
4.1
8.6
0.8

1.9
1.2
3.4
4.4
0.2

0.5
0.6
0.0
1.1
0.3

Adjective Rating Scales
Sedative
Stimulated

2.1
3.1

0.4
8.9

0.4
1.1

Visual Analog Scales
Active/Alert/Energetic
Any Effects
Bad Effects
Euphoric
Good Effects
High
Irregular Heartbeat
Like Drug
Nauseous/Sick to Stomach
Nervous/Anxious
Pay For
Performance Impaired
Performance Improved
Restless
Rush
Shaky/Jittery
Sluggish/Fatigued/Lazy
Stimulated
Talkative/Friendly
Willing to Take Again

1.6
7.4
0.4
4.6
10.4
5.8
5.5
13.9
4.4
1.8
10.7
2.6
3.8
4.2
13.4
3.8
2.3
6.2
2.2
5.6

5.3
10.5
2.6
2.7
9.8
9.2
5.3
9.8
2.3
2.1
6.2
2.9
2.0
2.5
5.8
3.4
1.8
6.1
3.2
9.3

0.7
0.5
0.3
2.0
0.6
0.3
1.8
0.6
1.7
0.9
0.9
1.9
0.4
1.6
0.1
3.6
1.3
0.5
0.6
1.2
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Table 4. Peak means for physiological indices and subject-rated drug-effects
measures (Means [SEM]).
Peak
Outcome
Measures
Physiological
Diastolic Pressure
Heart Rate
Mean Arterial Pressure
Systolic Pressure
Temperature

Placebo

d-Amphetamine (0 mg)
METH
METH
METH
10 mg
20 mg
30 mg

80.8 (3.7)
79.2 (3.8)
94.2 (3.3)
120.5 (3.7)
98.1 (0.2)

83.1 (2.8)
85.9 (5.0)
99.9(2.1)
133.0 (3.9)
98.1 (0.2)

81.5 (1.5)
83.5 (4.9)
98.2 (1.7)
131.5 (1.8)
98.0 (0.2)

83.9 (3.4)
87.0 (3.6)
100.8 (2.7)
133.1 (3.9)
98.0 (0.1)

Adjective Rating Scale
Sedative
Stimulated

3.9 (1.3)
6.8 (2.6)

4.4 (1.2)
10.9 (1.9)

3.4 (1.2)
11.8 (1.8)

4.4 (1.6)
14.1 (2.2)

Visual Analog Scale
Active/Alert/Energetic
Any Effect
Bad Effect
Euphoric
Good Effect
High
Irregular/Racing Heartbeat
Like Drug
Nauseous/Sick to Stomach
Nervous/Anxious
Pay For
Performance Impaired
Performance Improved
Restless
Rush
Shaky/Jittery
Sluggish/Fatigued/Lazy
Stimulated
Talkative/Friendly
Willing to Take Again

7.9 (3.1)
6.1 (3.3)
2.1 (1.0)
2.0 (0.8)
5.8 (3.2)
6.5 (3.3)
2.9 (1.2)
6.8 (2.9)
3.8 (1.4)
2.6 (1.1)
4.6 (2.3)
2.4 (1.0)
6.0 (2.8)
2.1 (0.7)
5.0 (2.9)
2.2 (0.9)
4.8 (2.2)
7.1 (3.7)
13.2 (5.4)
6.2 (2.8)

30.1 (11.0)
29.9 (9.8)
2.6 (1.4)
6.6 (4.0)
30.4 (9.5)
29.2 (9.5)
5.9 (2.7)
36.0 (10.4)
8.5 (3.4)
11.4 (7.7)
30.5 (10.9)
6.1 (3.0)
21.2 (11.3)
7.5 (2.5)
23.1 (10.0)
26.1 (11.4)
10.4 (6.4)
27.2 (10.0)
31.4 (11.8)
45.0 (13.0)

32.4 (12.3)
34.2 (10.4)
3.9 (1.8)
5.8 (2.8)
34.1 (10.7)
33.0 (10.4)
7.4 (5.6)
39.1 (11.0)
5.0 (2.2)
4.8 (2.5)
31.2 (12.6)
5.2 (2.8)
21.2 (12.5)
9.4 (4.4)
28.0 (10.8)
5.2 (2.6)
11.6 (6.6)
28.9 (11.0)
30.5 (12.5)
47.0 (13.6)

37.5 (12.1)
46.2 (9.8)
5.4 (2.6)
17.8 (8.8)
44.2 (9.7)
42.5 (9.8)
22.5 (8.9)
44.8 (10.0)
9.1 (3.7)
13.6 (6.6)
39.2 (12.2)
22.4 (11.3)
19.6 (11.2)
11.1 (4.0)
34.0 (11.3)
21.9 (8.7)
11.1 (5.8)
35.8 (10.6)
38.8 (12.9)
53.1 (12.1)
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Table 4 (continued). Peak means for physiological indices and subject-rated
drug effects measures (Means [SEM]).
Peak
Outcome
Measures
Physiological
Diastolic Pressure
Heart Rate
Mean Arterial Pressure
Systolic Pressure
Temperature

METH
0 mg

d-Amphetamine (40 mg)
METH
METH
METH
10 mg
20 mg
30 mg

75.4 (3.6)
86.9 (3.2)
91.1 (2.6)
119.6 (2.1)
97.9 (0.2)

82.5 (2.0)
88.0 (4.3)
97. 0 (1.7)
125.1 (3.1)
98.0 (0.2)

80.6 (2.0)
84.0 (3.1)
95.8 (2.1)
125.0 (2.3)
98.0 (0.1)

81.8 (2.5)
88.4 (4.1)
97.9 (2.2)
128.0 (2.4)
97.9 (0.2)

Adjective Rating Scale
Sedative
Stimulated

2.1 (0.6)
6.2 (1.8)

3.0 (0.9)
9.2 (2.0)

3.2 (1.1)
9.8 (1.8)

4.0 (1.2)
10.2 (1.9)

Visual Analog Scale
Active/Alert/Energetic
Any Effect
Bad Effect
Euphoric
Good Effect
High
Irregular/Racing Heartbeat
Like Drug
Nauseous/Sick to Stomach
Nervous/Anxious
Pay For
Performance Impaired
Performance Improved
Restless
Rush
Shaky/Jittery
Sluggish/Fatigued/Lazy
Stimulated
Talkative/Friendly
Willing to Take Again

11.5 (7.3)
3.8 (1.4)
1.9 (1.0)
2.1 (1.0)
3.8 (1.5)
4.1 (1.6)
1.9 (0.7)
3.5 (1.3)
2.4 (0.9)
2.6 (1.2)
3.2 (1.4)
2.2 (1.3)
2.6 (1.2)
3.5 (1.6)
1.6 (0.8)
2.9 (1.2)
6.8 (4.2)
3.6 (1.6)
11.8 (7.8)
4.0 (1.8)

22.4 (11.3)
20.1 (11.4)
2.8 (1.4)
4.2 (2.7)
18.4 (11.7)
20.8 (11.5)
3.5 (1.5)
21.2 (11.2)
4.2 (2.0)
5.2 (2.6)
18.2 (11.2)
3.1 (1.2)
13.8 (10.9)
4.2 (1.4)
16.0 (12.0)
5.0 (2.3)
3.2 (1.3)
17.5 (10.8)
23.6 (12.8)
22.0 (11.6)

29.4 (9.0)
26.9 (7.0)
2.9 (1.2)
5.8 (3.7)
25.8 (7.4)
27.9 (7.3)
4.1 (1.7)
29.2 (8.7)
4.6 (2.5)
4.0 (2.5)
27.1 (9.0)
5.0 (2.8)
14.8 (8.1)
6.6 (3.2)
20.8 (8.3)
7.6 (3.9)
9.8 (5.7)
25.0 (7.9)
27.2 (10.0)
28.8 (9.2)

31.2 (9.5)
33.8 (7.0)
4.6 (2.1)
7.5 (4.2)
34.5 (7.6)
33.5 (7.3)
6.9 (2.9)
35.2 (7.9)
5.6 (2.2)
7.6 (4.1)
30.0 (9.3)
5.1 (2.2)
15.6 (9.2)
7.8 (3.1)
28.4 (9.6)
8.5 (4.1)
7.6 (3.8)
26.6 (8.6)
27.6 (10.2)
42.8 (11.8)
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Area-Under-the-Time-Action Curve. Analyses of area-under-the-time-action
curve data revealed a pattern of effects similar to those observed with analysis of
peak effect data. F-values and means and for these analyses are shown in
Tables 5 and 6.
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Table

5.

F-values

from

area-under-the-time-action

curve

analysis

for

physiological indices and subject-rated drug-effects measures (Bold
indicates a significant F-value).
d-AMPH

METH

METH x
d-AMPH

0.9
0.9
6.0
12.4
0.1

0.4
0.4
5.1
7.7
0.3

0.3
0.3
0.2
0.5
0.7

Adjective Rating Scale
Sedative
Stimulated

2.0
3.4

0.3
10.5

0.1
2.9

Visual Analog Scale
Active/Alert/Energetic
Any Effects
Bad Effects
Euphoric
Good Effects
High
Irregular/Racing Heartbeat
Like Drug
Nauseous/Sick to Stomach
Nervous/Anxious
Pay For
Performance Impaired
Performance Improved
Restless
Rush
Shaky/Jittery
Sluggish/Fatigued/Lazy
Stimulated
Talkative/Friendly
Willing to Take Again

5.5
16.9
0.5
4.5
21.9
11.3
7.0
17.3
4.2
1.6
9.4
2.2
3.2
6.2
9.9
2.2
2.2
7.7
6.8
12.3

5.0
7.8
2.5
2.6
7.4
7.0
7.5
7.2
2.3
2.0
4.9
3.6
2.0
2.4
3.9
3.1
1.9
4.7
3.5
7.9

0.2
1.0
0.3
2.4
0.8
0.7
1.8
0.6
0.8
2.1
0.7
2.0
0.2
1.4
0.1
3.6
1.2
0.1
0.6
0.8

Outcome Measures
Physiological
Diastolic Pressure
Heart Rate
Mean Arterial Pressure
Systolic Pressure
Temperature
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Table 6. Means for area-under-the-time-action curve for physiological indices
and subject-rated drug-effect measures (Means [SEM]).
AUC
Outcome Measures
Physiological
Diastolic Pressure
Heart Rate
Mean Arterial Pressure
Systolic Pressure
Temperature
Adjective Rating Scale
Sedative
Stimulated
Visual Analog Scale
Active/Alert/Energetic
Any Effects
Bad Effects
Euphoric
Good Effects
High
Irregular/Racing
Heartbeat
Like Drug
Nauseous/Sick to
Stomach
Nervous/Anxious
Pay For
Performance Impaired
Performance Improved
Restless
Rush
Shaky/Jittery
Sluggish/Fatigued/Lazy
Stimulated
Take Again
Talkative/Friendly

d-Amphetamine (0 mg)
METH
METH
METH
10 mg
20 mg
30 mg

Placebo
75.9 (3.9)
75.9 (3.9)
90.1 (2.8)
115.8 (2.9)
97.8 (0.2)

77.1 (3.2)
77.1 (3.2)
9.8 (1.9)
123.0 (2.8)
97.7 (0.2)

77.9 (4.3)
77.9 (4.3)
94.0 (1.4)
125.5 (2.1)
97.7 (0.2)

79.5 (3.1)
79.5 (3.1)
97.0 (2.9)
128.0 (3.2)
97.8 (0.1)

2.7 (0.8)
5.5 (2.0)

3.2 (0.9)
8.8 (1.5)

2.7 (0.9)
10.0 (2.0)

3.2 (1.2)
12.2 (1.9)

6.1 (2.8)
4.2 (2.5)
1.3 (0.6)
1.3 (0.5)
3.9 (2.2)
4.1 (2.5)
1.7 (0.7)

22.2 (8.6)
19.2 (6.5)
2.0 (1.1)
4.1 (2.6)
18.1 (6.7)
19.1 (6.8)
4.2 (2.0)

25.9 (10.9)
23.6 (8.9)
2.5 (1.3)
4.0 (2.2)
23.5 (9.1)
23.6 (9.0)
5.1 (2.5)

30.3 (10.1)
33.6 (8.1)
3.3 (1.5)
10.0 (5.1)
33.2 (7.7)
32.0 (8.4)
10.7 (3.3)

3.9 (2.2)
2.0 (0.8)

22.9 (7.9)
4.5 (1.6)

28.4 (10.4)
3.6 (1.7)

34.7 (8.3)
6.2 (3.0)

1.6 (0.6)
2.4 (1.2)
1.5 (0.7)
4.0 (2.0)
1.5 (0.6)
3.9 (2.5)
1.5 (0.6)
3.3 (1.8)
4.4 (2.5)
3.7 (2.1)
7.1 (3.0)

4.2 (2.3)
21.6 (8.5)
3.6 (1.9)
14.6 (8.2)
4.8 (1.8)
15.3 (7.4)
7.9 (4.0)
8.6 (5.7)
16.8 (7.3)
27.8 (8.4)
22.5 (9.6)

3.2 (1.7)
25.6 (11.3)
3.1 (1.7)
17.1 (10.7)
6.4 (3.3)
19.4 (9.8)
3.4 (2.0)
7.8 (4.6)
22.3 (9.6)
33.3 (10.5)
25.6 (11.4)

10.0 (5.7)
30.6 (9.6)
6.9 (2.8)
14.1 (8.1)
6.9 (2.4)
23.3 (7.9)
13.5 (6.3)
8.2 (4.5)
22.8 (7.1)
39.4 (9.2)
29.7 (10.7)
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Table 6 (continued). Means for area-under-the-time-action curve for
physiological indices and subject-rated drug-effect
measures (Means [SEM]).
AUC
Outcome Measures

Placebo

Physiological
Diastolic Pressure
Heart Rate
Mean Arterial Pressure
Systolic Pressure
Temperature

80.5 (3.2)
80.5 (3.2)
86.6 (2.6)
112.8 (2.4)
97.7 (0.2)

80.5 (3.5)
80.5 (3.5)
91.8 (2.1)
120.0 (3.2)
97.6 (0.2)

78.3 (3.2)
78.3 (3.2)
91.0 (1.8)
119.7 (2.0)
97.9 (0.2)

81.2 (3.8)
81.2 (3.8)
92.7 (2.2)
121.4 (2.2)
97.6 (0.2)

1.8 (0.5)
6.0 (1.7)

2.4 (0.9)
7.6 (2.0)

2.5 (0.8)
8.5 (1.9)

2.8 (0.6)
8.2 (1.8)

3.9 (1.7)
2.4 (1.0)
1.2 (0.6)
1.4 (0.7)
2.5 (1.0)
2.6 (1.1)
1.2 (0.5)

18.0 (10.1)
13.6 (9.1)
1.8 (0.9)
2.8 (1.7)
13.5 (10.2)
14.8 (10.0)
2.0 (0.8)

21.9 (8.3)
17.0 (6.4)
1.9 (0.8)
3.4 (2.4)
18.0 (6.6)
18.3 (6.4)
2.6 (1.0)

22.8 (8.3)
21.4 (6.4)
3.1 (1.5)
3.6 (2.2)
22.7 (6.7)
21.0 (6.5)
4.4 (1.7)

2.4 (1.0)
1.4 (0.5)

15.9 (10.0)
2.5 (1.3)

21.1 (8.0)
3.0 (1.5)

24.2 (7.2)
3.9 (1.6)

2.0 (0.9)
2.2 (0.9)
1.4 (0.7)
1.3 (0.6)
2.4 (1.1)
1.1 (0.5)
2.2 (1.0)
2.6 (1.4)
2.4 (1.2)
2.2 (1.0)
5.8 (3.0)

2.5 (1.1)
13.4 (10.0)
1.9 (0.8)
11.9 (10.1)
2.5 (0.8)
12.9 (10.3)
2.9 (1.3)*
2.2 (0.9)
10.9 (7.0)
18.0 (10.4)
18.7 (10.9)

2.8 (1.7)
21.0 (8.8)
3.0 (1.7)
12.1 (7.2)
3.9 (1.7)
14.3 (6.4)
3.7 (1.9)
7.5 (5.0)
17.8 (6.7)
21.8 (8.8)
20.7 (9.2)

4.6 (2.1)
21.2 (8.0)
3.2 (1.4)
12.1 (8.0)
4.5 (1.5)
18.2 (7.6)
5.0 (2.4)
5.1 (2.8)
18.2 (7.4)
29.7 (8.6)
20.6 (9.0)

Adjective Rating
Scale
Sedative
Stimulated
Visual Analog Scale
Active/Alert/Energetic
Any Effects
Bad Effects
Euphoric
Good Effects
High
Irregular/Racing
Heartbeat
Like Drug
Nauseous/Sick to
Stomach
Nervous/Anxious
Pay For
Performance Impaired
Performance Improved
Restless
Rush
Shaky/Jittery
Sluggish/Fatigued/Lazy
Stimulated
Take Again
Talkative/Friendly

d-Amphetamine (0 mg)
METH
METH
METH
10 mg
20 mg
30 mg
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Visual Analog Scales
Peak Effect. ANOVA revealed a significant interaction of methamphetamine
and d-amphetamine for ratings of Shaky or Jittery (Table 3). This interaction was
attributable to 10 and 30 mg methamphetamine increasing these ratings above
placebo levels during placebo maintenance but not during d-amphetamine
maintenance (Table 4).
ANOVA revealed a main effect of methamphetamine and d-amphetamine, but
not an interaction of these factors, for ratings of Any Effect, Good Effects, High,
Like Drug, Pay For, Rush, Stimulated, Talkative or Friendly and Willing to Take
Again. Methamphetamine generally increased these ratings as a function of dose
during both placebo and d-amphetamine maintenance. However, these ratings
were lower during d-amphetamine maintenance relative to placebo maintenance.
F-values and means are shown in Tables 3 and 4, respectively. Figures 2 and 3
show data for two of these measures, ratings of Like Drug and Willing to Take
Again, respectively.
ANOVA revealed only a main effect of methamphetamine for ratings of
Active, Alert, Energetic; Irregular or Racing Heartbeat; and Talkative or Friendly.
Methamphetamine increased these ratings as function of dose regardless of the
maintenance condition. F-values and means are shown in Tables 3 and 4,
respectively.
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Figure 2.
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Figure 3.
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Area-Under-the-Time-Action Curve. Analyses of area-under-the-time-action
curve data revealed a pattern of effects similar to those observed with analysis of
peak effect data. F-values and means and for these analyses are shown in
Tables 5 and 6, respectively.
Cognitive Effects of Methamphetamine During d-Amphetamine
Maintenance
Cued Go/No-Go Task. ANOVA revealed a significant interaction of
methamphetamine and d-amphetamine for inhibitory failures to a no-go target
following a no-go cue on the Cued Go/No-Go task (Table 7). This interaction was
due to the methamphetamine having little effect during placebo maintenance, but
dose-dependently increasing inhibitory failures during d-amphetamine
maintenance (Table 8; Figure 4). There were no significant effects on inhibitory
failures for a no-go target following a go cue or on reaction time to go targets
following either go or no-go targets.
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Table 7. F-values of cognitive tasks after methamphetamine administration (Bold
indicates a significant F-value).
Outcome Measures
Visual Probe Task
Reaction Time Cocaine
Reaction Time Neutral
Attention Bias Score
Cued Go/No-Go Task
Reaction Time
Go Cue
No Go Cue
Inhibitory Failures
Go Cue
No Go Cue
Balloon Analog Risk Task
Percent Exploded

d-AMPH Dose

METH Dose

METH x
d-AMPH

0.0
0.0
0.0

0.4
0.6
0.0

0.0
0.6
1.7

0.4
2.7

1.9
2.1

0.6
1.3

0.8
1.6

0.5
1.3

0.7
3.2

0.6

0.9

1.8
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Table 8. Means of cognitive tasks after methamphetamine administration (Means [SEM]).
Outcome Measures
Visual Probe Task
Reaction Time Cocaine
Reaction Time Neutral
Attention Bias Score
Cued Go/No-Go Task
Reaction Time
Go Cue
No Go Cue
Inhibitory Failures
Go Cue
No Go Cue
Balloon Analog Risk Task
Percent Exploded

Placebo

d-Amphetamine (0 mg)
METH
METH
METH
10 mg
20 mg
30 mg

396.6 (32.5)
406.6 (33.4)
10.0 (11.6)

391.6 (26.3)
393.6 (28.2)
2.0 (6.1)

378.5 (25.0)
397.4 (31.4)
18.9 (7.7)

392.1 (29.5)
402.8 (26.9)
10.6 (12.7)

291.8 (16.0)
328.4 (17.4)

285.6 (12.6)
326.9 (13.2)

280.0 (6.5)
326.5 (14.9)

285.6 (9.4)
322.2 (12.8)

0.1 (0.0)
0.0 (0.0)

0.2 (0.0)
0.0 (0.0)

0.2 (0.0)
0.0 (0.0)

0.2 (0.0)
0.0 (0.0)

0.4 (0.0)

0.3 (0.0)

0.4 (0.0)

0.3 (0.0)
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Table 8 (continued). Means of cognitive tasks after methamphetamine administration (Means [SEM]).
Outcome Measures
Visual Probe Task
Reaction Time Cocaine
Reaction Time Neutral
Attention Bias Score
Cued Go/No-Go Task
Reaction Time
Go Cue
No Go Cue
Inhibitory Failures
Go Cue
No Go Cue
Balloon Analog Risk Task
Percent Exploded

METH
0 mg

d-Amphetamine (40 mg)
METH
METH
10 mg
20 mg

METH
30 mg

393.5 (30.2)
403.2 (31.0)
9.7 (6.3)

388.0 (20.3)
408.9 (18.3)
20.9 (9.1)

382.4 (22.7)
381.0 (23.9)
-1.3 (6.2)

389.9 (30.1)
399.7 (30.6)
9.8 (5.9)

299.3 (20.7)
337.8 (22.8)

284.4 (10.5)
314.0 (16.1)

274.9 (8.1)
312.9 (16.3)

274.7 (5.1)
311.6 (13.4)

0.2 (0.1)
0.0 (0.0)

0.2 (0.0)
0.0 (0.0)

0.2 (0.0)
0.1 (0.0)

0.2 (0.1)
0.1 (0.0)

0.3 (0.0)

0.3 (0.0)

0.3 (0.0)

0.3 (0.0)
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Figure 4.
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Visual Probe Task. There were no significant effects on the Visual Probe task.
F-values and means for this task after the administration of methamphetamine
are shown in Tables 7 and 8, respectively.
Balloon Analog Risk Task (BART). There were no significant effects on the
BART. F-values and means for this task after the administration of
methamphetamine are shown in Tables 7 and 8, respectively.
Physiological Effects of Methamphetamine During d-Amphetamine
Maintenance
Peak Effect. ANOVA revealed a main effect of methamphetamine and damphetamine, but not an interaction of these factors, for systolic blood pressure
(Figure 5). Methamphetamine generally increased systolic blood pressure as a
function of dose during placebo and d-amphetamine maintenance. The pressureincreasing effects of methamphetamine on systolic blood pressure were
attenuated during d-amphetamine maintenance relative to placebo maintenance.
There were no significant effects on heart rate, diastolic pressure of body
temperature. F-values and means are shown in Tables 3 and 4, respectively.
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Figure 5.
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Area-under-the-time-action curve (AUC). Analyses of area-under-the-timeaction curve data revealed a pattern of effects similar to those observed with
analysis of peak effect data. F-values and means and for these analyses are
shown in Tables 5 and 6, respectively.
Cognitive Effects of d-Amphetamine and Placebo Maintenance
Visual Probe Task. d-Amphetamine maintenance did not significantly affect of
the measures on the Visual Probe Task. T-values and means and for these
analyses are shown in Tables 9 and 10, respectively.
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Table 9. T-values of cognitive tasks during maintenance days (Bold indicates a
significant t-value).
Outcome Measure
T-Value
Visual Probe Task
Reaction Time Cocaine
Reaction Time Neutral
Attention Bias Score

1.0
0.5
1.0

Cocaine Stroop
Reaction Time Cocaine
Reaction Time Neutral
Attention Bias Score

0.0
2.1
1.2

Cued Go/No-Go Task
Reaction Time
Go Cue
No Go Cue
Inhibitory Failures
Go Cue
No Go Cue

1.2
3.6
0.0
1.1

Balloon Analog Risk Task
Percent Exploded

0.5

Digit Symbol Substitution Task
Trials Completed
Trails Correct

0.0
0.9
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Table 10. Means of cognitive tasks during maintenance days (Means [SEM]).
Outcome Measure

d-AMPH
(0 mg) AM

d-AMPH
(0 mg) PM

d-AMPH
(40 mg) AM

d-AMPH
(40 mg) PM

Visual Probe Task
Reaction Time Cocaine
Reaction Time Neutral
Attention Bias Score

396.9 (23.9)
401.4 (26.0)
4.5 (7.2)

385.1 (22.6)
385.2 (22.2)
0.1 (4.1)

382.9 (26.7)
390.9 (27.9)
8.0 (6.2)

380.0 (33.5)
386.6 (29.2)
6.5 (6.4)

Cocaine Stroop
Reaction Time Cocaine
Reaction Time Neutral
Attention Bias Score

761.9 (41.4)
770.3 (40.8)
-8.4 (17.8)

751.2 (39.6)
745.6 (39.6)
5.6 (7.5)

751.8 (43.7)
733.4 (37.6)
18.4 (19.1)

760.7 (43.0)
732.2 (38.2)
28.5 (12.6)

295.5 (11.8)
324.2 (12.6)

285.2 (9.3)
324.7 (12.4)

287.6 (9.8)
304.8 (13.0)

282.3 (8.2)
308.6 (13.4)

0.1 (0.0)
0.0 (0.0)

0.2 (0.1)
0.0 (0.0)

0.1 (0.0)
0.0 (0.0)

0.2 (0.0)
0.0 (0.0)

Balloon Analog Risk
Task
Percent Exploded

0.3 (0.1)

0.3 (0.0)

0.2 (0.0)

0.3 (0.0)

Digit Symbol
Substitution Task
Trials Completed
Trails Correct

44.8 (3.2)
42.0 (3.2)

46.9 (3.2)
43.5 (2.8)

45.2 (3.7)
40.2 (4.1)

46.4 (3.7)
40.4 (6.3)

Cued Go/No-Go Task
Reaction Time
Go Cue
No Go Cue
Inhibitory Failures
Go Cue
No Go Cue
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Cocaine Stroop Task. d-Amphetamine maintenance did not significantly affect
any of the measures on the Cocaine Stroop Task. T-values and means and for
these analyses are shown in Tables 9 and 10, respectively.
Cued Go/No Go Task. d-Amphetamine maintenance did not significantly
affect inhibitory failures to a no-go target following a no-go cue on the Cued
Go/No-Go task nor did d-amphetamine significantly affect inhibitory failures to a
no-go target following a go cue on the Cued Go/No-Go task. d-Amphetamine
maintenance decreased reaction time to a go target following a no-go cue. dAmphetamine maintenance did not affect reaction time to a go target following a
go cue. T-values and means and for these analyses are shown in Tables 9 and
10, respectively.
Balloon Analog Risk Task (BART). d-Amphetamine maintenance did not
significantly affect the percent of balloons exploded. T-values and means and for
these analyses are shown in Tables 9 and 10, respectively.
Digit-Symbol-Substitution Task (DSST). d-Amphetamine maintenance did not
significantly affect the number of trials completed and trials correct. T-values and
means and for these analyses are shown in Tables 11 and 12, respectively.
Grooved Pegboard Task. d-Amphetamine maintenance did not significantly
affect performance on the Grooved Pegboard Task. F-values and means and for
these analyses are shown in Tables 11 and 12, respectively.
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Table 11. F-values for grooved pegboard during maintenance days (Bold indicates a significant F-value).
Outcome
Measure
Grooved
Pegboard

d-AMPH

Time

Replication

4.2

11.1

12.5

d-AMPH x
Time
0.3
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d-AMPH x
Replication
2.7

Time x
Replication
0.8

d-AMPH x Time
x Replication
0.4

Table 12. Means of grooved pegboard during maintenance days (Means [SEM]).

Trial Number
One
Two

d-AMPH (0 mg)
Maintenance
AM
PM
91.4 (2.8)
86.7 (2.7)
86.8 (2.0)
84.9 (2.3)
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d-AMPH (40 mg)
Maintenance
AM
PM
93.5 (2.9)
92.1 (2.6)
87.3 (3.0)
85.4 (2.2)

N-Back Task. d-Amphetamine maintenance did not significantly affect
performance on the N-Back Task. F-values and means and for these analyses
are shown in Tables 13 and 14, respectively.
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Table 13. F-values for N-Back Task during maintenance days (Bold indicates a significant F-value).
Outcome Measure
N-Back
Accuracy
Target
Non-Target
Reaction Time
Target
Non-Target

Number
Back

d-AMPH

Time

Back x
d-AMPH

Back x
Time

d-AMPH x
Time

Back x
d-AMPH x
Time

3.0
0.4

2.1
0.5

0.3
0.5

0.3
0.5

3.1
0.5

0.0
0.5

0.1
0.1

1.64
3.1

1.59
0.0

0.03
0.1

2.22
0.2

2.09
0.0

5.20
2.1

4.56
2.2
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Table 14. Means of N-Back Task during maintenance days (Means [SEM]).
N-Back
One Back
Accuracy
Target
Non-Target
Reaction Time
Target
Non-Target
Two Back
Accuracy
Target
Non-Target
Reaction Time
Target
Non-Target
Three Back
Accuracy
Target
Non-Target
Reaction Time
Target
Non-Target

d-AMPH (0 mg)
AM
PM

d-AMPH (40 mg)
AM
PM

1.0 (0.0)
0.8 (0.1)

0.9 (0.1)
0.9 (0.0)

0.8 (0.1)
0.8 (0.1)

0.7 (0.1)
0.8 (0.1)

643.8 (63.8)
569.8 (98.2)

637.0 (58.5)
563.4 (70.2)

646.1 (68.6)
589.0 (77.2)

669.7 (71.9)
575.9 (73.0)

0.8 (0.1)
0.9 (0.0)

0.9 (0.0)
0.9 (0.1)

0.7 (0.1)
0.8 (0.1)

0.8 (0.1)
0.8 (0.1)

838.6 (113.0)
768.4 (143.7)

762.0 (96.9)
661.8 (65.3)

653.1 (99.0)
683.2 (106.0)

777.7 (117.7)
750.7 (105.8)

0.7 (0.1)
0.9 (0.0)

0.8 (0.1)
0.9 (0.1)

0.6 (0.1)
0.8 (0.1)

0.7 (0.1)
0.8 (0.1)

847.9 (146.3)
787.1 (116.9)

688.4 (95.6)
666.0 (70.4)

718.9 (138.8)
662.7 (104.7)

787.6 (130.7)
761.6 (113.3)
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Chapter Six. Discussion
Overall, methamphetamine acted as a reinforcer and was self-administered
significantly more than placebo regardless of maintenance condition. dAmphetamine maintenance attenuated some of the subject-rated drug-effects of
methamphetamine. There were generally no significant differences after placebo
or methamphetamine administration on the cognitive battery during placebo and
d-amphetamine maintenance. Methamphetamine was safe and well-tolerated
during both placebo and d-amphetamine maintenance. Below is a discussion of
these findings as they pertain to the current literature.
Behavioral
Intranasal methamphetamine was self-administered by participants more than
placebo. This was shown across the range of doses with participants earning
between eight and nine of the ten possible drug choices. This is consistent with
previous research that has shown that intranasal methamphetamine functions as
a robust reinforcer (Kirkpatrick, et al., 2011). Intranasal dosing was selected as
the route of administration as it produces robust reinforcing effects.
However, d-amphetamine maintenance did not significantly reduce selfadministration of methamphetamine. This result is similar to the results of two
recent clinical trials that showed d-amphetamine treatment did not reduce
methamphetamine use significantly compared to placebo (Galloway, et al., 2011,
Longo, et al., 2009). However, these findings are inconsistent with results of
another clinical trial that showed that d-amphetamine pretreatment reduced illicit
use of amphetamine (Moeller, Schmitz, Herin, & Kjome, 2008). Similar to this
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clinical trial, the data from the present study shows a clear trend of a downward
shift in self-administration during d-amphetamine maintenance, however this
decrease was not statistically significant. This suggests that it may be that a
higher dose would be necessary to show a significant decrease in selfadministration. However, the higher doses, up to 110 mg/day have been tested in
previous studies and did not significantly reduced methamphetamine selfadministration compared to placebo (Galloway, et al., 2011, Longo, et al., 2009),
which suggests that the lack of a reduction of self-administration of
methamphetamine during d-amphetamine maintenance may not be solely due to
the dose tested. Overall, the concordance between the self-administration data
and results of clinical trials shows that self-administration has predictive validity
for outcomes that have been observed in clinical trials.
Methamphetamine administered alone dose dependently increased positive
subject-rated drug-effects (e.g., Like Drug; Willing to Take Again). This is
consistent with previous literature that shows methamphetamine increases
ratings of positive subject-rated drug-effects (Hart, et al., 2008; Hart, et al., 2011;
Lile, Stoops, Glaser, Hays, & Rush, 2011; Perez, et al., 2008; Rush, Stoops, Lile,
Glaser, & Hays, 2011; Rush, Stoops, Lile, Glaser, & Hays, 2011; Sevak, et al.,
2011; Stoops, 2006). d-Amphetamine maintenance attenuated some of the
positive subject-rated drug-effects. The reduction of subject-rated drug-effects of
methamphetamine during d-amphetamine maintenance is consistent with a
previous study that showed 45 mg/day d-amphetamine reduced the subject-rated
drug-effects of methamphetamine (Rush, Stoops, Lile, Glaser, & Hays, 2011).
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The positive results of d-amphetamine to reduce subject-rated drug-effects of
methamphetamine suggest that subject-rated drug-effects have poor predictive
validity to model results observed in the clinic, producing false positives. Other
medications have reduced the subject-rated drug-effects of stimulants, but were
not effective clinically. Representative medications that have decreased subjectrated drug-effects, but failed to decrease drug use in the clinic include
risperidone (Grabowski, et al., 2000; Meredith, et al., 2009; Wachtel, Ortengren,
& de Wit, 2002) and aripiprazole (Sevak, et al., 2011; Stoops, 2006; Tiihonen, et
al., 2007).
While the data from the current study combined with the findings of recent
clinical trials (Galloway, et al., 2011, Longo, et al., 2009) suggest that damphetamine may not be a viable pharmacotherapy for methamphetamine
dependence, translational literature from studies testing agonist replacement for
the treatment of cocaine suggest that a different agonist medication may be
found that is an effective treatment (reviewed in: Herin, Rush, & Grabowski,
2010; Moeller, Schmitz, Herin, & Kjome, 2008). Preclinical studies with rats and
rhesus monkeys have shown that maintenance with d-amphetamine decreases
cocaine self-administration (Chiodo, Läck, Roberts, 2008; Chiodo & Roberts,
2009; Czoty, Gould, Martelle, & Nader, 2011; Czoty, Martelle, & Nader, 2010;
Foltin & Evans, 1998; Negus & Mello, 2003a; Negus & Mello, 2003b; Peltier, Li,
Lytle, Taylor, & Emmett-Oglesby, 1996). Human laboratory studies with healthy
non-treatment seeking cocaine users have shown that maintenance on damphetamine reduced some of the positive subjective effects of intranasal
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cocaine and decreased self-administration of 20 mg of cocaine (Rush, Stoops, &
Hays, 2009; Rush, Stoops, Sevak, & Hays, 2010). Finally, clinical trials have
shown positive results using d-amphetamine as a potential treatment for cocaine
dependence (Grabowski, et al., 2001; Grabowski, et al., 2004; Shearer, Wodak,
van Beek, Mattick, & Lewis, 2003).
Cognitive
Effects of d-Amphetamine and Placebo Maintenance. Generally there were
not significant differences in performance on the cognitive battery between damphetamine and placebo maintenance. The only difference observed was that
during d-amphetamine maintenance participants were quicker to respond to a go
target following a no-go cue on the cued go/no-go task. As d-amphetamine is
used to treat psychiatric disorders with deficits that have been proposed to be
found in chronic stimulant abusers, the lack of difference in performance between
maintenance conditions suggests that there may not be deficits present.
Effects of Methamphetamine during d-amphetamine maintenance. Generally
there were not differences in performance observed after methamphetamine
administered either alone or in combination with d-amphetamine. The only
significant difference observed was that participants had increased inhibitory
failures to a no-go target following a no-go cue on the cued go/no-go task. This
difference was attributed to a dose dependent decrease in performance when
methamphetamine was administered during d-amphetamine maintenance only.
This increase in inhibitory failures may be attributed to participants having

72

received two stimulant medications and the behavioral effects of a general
increase activity.
It is possible that the participants did not have significant deficits in cognitive
functioning, as suggested in a recent review (Hart, Marvin, Silver, & Smith,
2012). This review compiled previous studies that investigated cognitive
performance in methamphetamine users and compared the results found to
normative data for the assessments used when normative data was available. It
was found that while deficits may be apparent when performance is compared to
a control sample these deficits are not present when compared to age and
education matched normative data (Hart, Marvin, Silver, & Smith, 2012). It would
be expected that if impairments in cognitive functioning had existed, there should
have been significant improvements observed after d-amphetamine was
administered alone, but the only changes observed were a general reduction in
time for participants to respond to go targets on the cued go/no-go task.
Additionally, when methamphetamine and d-amphetamine were administered in
combination there was a decrease in inhibitory control observed on the cued
go/no-go task. The results of the present study combined with the recent review
of cognitive performance in chronic stimulant users suggest that cognitive deficits
may not be a viable target for treatment.
Physiological
Methamphetamine dose dependently increased systolic blood pressure
during both d-amphetamine and placebo maintenance. However, these
increases were attenuated during d-amphetamine maintenance. Additionally,
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while the increases in systolic blood pressure were statistically significant, it was
considered clinically insignificant and no participants were discharged from the
study for medical reasons. There were no significant effects on heart rate,
diastolic blood pressure, or temperature. Administration of methamphetamine
during d-amphetamine maintenance produced an attenuated increase in systolic
blood pressure, compared to administration of methamphetamine alone. This
attenuation during d-amphetamine maintenance may be attributed to cross
tolerance to the stimulating effects of methamphetamine. These findings are
consistent with prior studies that have shown that intranasal methamphetamine
administered is safe and well-tolerated (Hart, et al., 2008; Kirkpatrick, et al.,
2011; Lile, Stoops, Glaser, Hays, & Rush, 2011; Perez, et al. 2008; Rush,
Stoops, Lile, Glaser, & Hays, 2011; Rush, Stoops, Lile, Glaser, & Hays, 2011;
Sevak, Stoops, Hays, & Rush, 2009; Sevak, et al., 2011; Stoops, 2006).
Future Directions
Future research should investigate the use of other agonist medications and
combinations of medications for the treatment of methamphetamine dependence.
It is possible that a dopamine transporter blocker would be best used for the
treatment of methamphetamine abuse, as methamphetamine is a dopamine
releaser. This is supported by past research that has shown that d-amphetamine,
which is a dopamine releaser, has shown positive results for cocaine
dependence, however methylphenidate, a dopamine transport blocker was
ineffective. It is possible that methylphenidate may be an effective treatment for
methamphetamine abuse, which is currently being assessed in a clinical trial.
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Combinations of medications that are modestly effective alone, such as
bupropion and naltrexone, should also be tested to see if the interaction of the
medications is more effective than either medication alone. The combination of
pharmacotherapy and behavioral therapy should also be assessed. Previous
research has shown that the combination of levodopa and contingency
management was more effective for cocaine dependence than levodopa or
contingency management alone (Schmitz, et al., 2008). Additionally, future
research is needed to investigate cognitive performance in chronic stimulant
users to determine if it is a viable target for medications development.
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